{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:32:38Z","timestamp":1788834758535,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T00:00:00Z","timestamp":1720915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.cyto.2024.156696","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T14:52:10Z","timestamp":1721919130000},"page":"156696","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Inflammatory biomarkers and long-term outcome in young patients three months after a first myocardial infarction"],"prefix":"10.1016","volume":"182","author":[{"given":"Sofia","family":"Cederstr\u00f6m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Jernberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Samneg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Silveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Tornvall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Lundman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.cyto.2024.156696_b0005","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1161\/01.CIR.101.15.1767","article-title":"Plasma Concentration of Interleukin-6 and the Risk of Future Myocardial Infarction Among Apparently Healthy Men","volume":"101","author":"Ridker","year":"2000","journal-title":"Circulation"},{"issue":"9709","key":"10.1016\/j.cyto.2024.156696_b0010","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","author":"Kaptoge","year":"2010","journal-title":"Lancet"},{"issue":"10384","key":"10.1016\/j.cyto.2024.156696_b0015","first-page":"1293","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"The Lancet (british Edition)."},{"issue":"12","key":"10.1016\/j.cyto.2024.156696_b0020","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10289","key":"10.1016\/j.cyto.2024.156696_b0025","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"issue":"28","key":"10.1016\/j.cyto.2024.156696_b0030","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1093\/eurheartj\/ehab115","article-title":"Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials","volume":"42","author":"Fiolet","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cyto.2024.156696_b0035","article-title":"Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data","volume":"342","author":"Wensley","year":"2011","journal-title":"BMJ"},{"issue":"9822","key":"10.1016\/j.cyto.2024.156696_b0040","first-page":"1205","article-title":"Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies","volume":"379","author":"Sarwar","year":"2012","journal-title":"The Lancet (british Edition)."},{"issue":"9822","key":"10.1016\/j.cyto.2024.156696_b0045","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","article-title":"The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis","volume":"379","author":"Swerdlow","year":"2012","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.cyto.2024.156696_b0050","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jacc.2016.01.069","article-title":"Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials","volume":"67","author":"Stone","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.cyto.2024.156696_b0055","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ahj.2016.05.003","article-title":"The association of left ventricular ejection fraction with clinical outcomes after myocardial infarction: Findings from the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get With the Guidelines (GWTG) Medicare-linked database","volume":"178","author":"Sutton","year":"2016","journal-title":"Am Heart J."},{"issue":"7","key":"10.1016\/j.cyto.2024.156696_b0060","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1177\/2048872616661691","article-title":"Relation of inflammatory markers with myocardial and microvascular injury in patients with reperfused ST-elevation myocardial infarction","volume":"6","author":"Reindl","year":"2017","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"issue":"6","key":"10.1016\/j.cyto.2024.156696_b0065","first-page":"515","article-title":"Enhetlig diagnostik av hj\u00e4rtinfarkt - snabb utveckling p\u00e5 svenska sjukhus","volume":"95","author":"Jernberg","year":"1998","journal-title":"Lakartidningen"},{"issue":"5","key":"10.1016\/j.cyto.2024.156696_b0070","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2796.2005.01561.x","article-title":"Serum matrix metalloproteinase-3 concentration is influenced by MMP-3 \u22121612 5A\/6A promoter genotype and associated with myocardial infarction","volume":"258","author":"Samneg\u00e5rd","year":"2005","journal-title":"J. Intern. Med."},{"issue":"2","key":"10.1016\/j.cyto.2024.156696_b0075","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.atherosclerosis.2005.11.013","article-title":"Plasma interleukin (IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6","volume":"188","author":"Hulthe","year":"2006","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.cyto.2024.156696_b0080","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.atherosclerosis.2008.05.050","article-title":"Gender specific associations between matrix metalloproteinases and inflammatory markers in post myocardial infarction patients","volume":"202","author":"Samneg\u00e5rd","year":"2008","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.cyto.2024.156696_b0085","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/jir.2010.0036","article-title":"Genetic and environmental influences on the plasma interleukin-6 concentration in patients with a recent myocardial infarction: a case-control study","volume":"31","author":"Bennermo","year":"2011","journal-title":"J. Interferon Cytokine Res."},{"issue":"1","key":"10.1016\/j.cyto.2024.156696_b0090","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.atherosclerosis.2004.08.018","article-title":"A novel common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein","volume":"178","author":"Kovacs","year":"2005","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.cyto.2024.156696_b0095","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1538-7836.2005.01690.x","article-title":"Treatment with combined oral contraceptives induces a rise in serum C-reactive protein in the absence of a general inflammatory response","volume":"4","author":"Van Rooijen","year":"2006","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.cyto.2024.156696_b0100","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1023\/A:1010933404324","article-title":"Random Forests","volume":"45","author":"Breiman","year":"2001","journal-title":"Mach. Learn."},{"key":"10.1016\/j.cyto.2024.156696_b0105","doi-asserted-by":"crossref","first-page":"d548","DOI":"10.1136\/bmj.d548","volume":"342","year":"2011","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.cyto.2024.156696_b0110","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1111\/bcp.15191","article-title":"Dissecting the IL-6 pathway in cardiometabolic disease: A Mendelian randomization study on both IL6 and IL6R","volume":"88","author":"Cupido","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.cyto.2024.156696_b0115","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.atherosclerosis.2018.09.034","article-title":"The prognostic value of interleukin 6 in multiple chronic diseases and all-cause death: The Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"278","author":"Cainzos-Achirica","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cyto.2024.156696_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2020.106806","article-title":"Interleukin-6 level is a powerful predictor of long-term cardiovascular mortality in patients with acute coronary syndrome","volume":"135","author":"Gager","year":"2020","journal-title":"Vasc.Pharmacol."},{"issue":"2","key":"10.1016\/j.cyto.2024.156696_b0125","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/2048872619878075","article-title":"Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel","volume":"10","author":"Thomas","year":"2019","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"issue":"38","key":"10.1016\/j.cyto.2024.156696_b0130","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","article-title":"Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"39","author":"Ridker","year":"2018","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/j.cyto.2024.156696_b0135","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1161\/CIRCRESAHA.121.319077","article-title":"Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease","volume":"128","author":"Ridker","year":"2021","journal-title":"Circ. Res."},{"key":"10.1016\/j.cyto.2024.156696_b0140","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijcard.2018.02.062","article-title":"All roads lead to IL-6: A central hub of cardiometabolic signaling","volume":"259","author":"Libby","year":"2018","journal-title":"Int. J. Cardiol."},{"issue":"11","key":"10.1016\/j.cyto.2024.156696_b0145","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/01.CIR.0000158479.58589.0A","article-title":"Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein","volume":"111","author":"Maier","year":"2005","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.cyto.2024.156696_b0150","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s00392-018-1387-z","article-title":"Plasma interleukin 6 levels are associated with cardiac function after ST-elevation myocardial infarction","volume":"108","author":"Groot","year":"2019","journal-title":"Clin Res Cardiol."},{"issue":"2","key":"10.1016\/j.cyto.2024.156696_b0155","doi-asserted-by":"crossref","first-page":"e001869","DOI":"10.1136\/openhrt-2021-001869","article-title":"High levels of interleukin-6 are associated with final infarct size and adverse clinical events in patients with STEMI","volume":"8","author":"T\u00f8llefsen","year":"2021","journal-title":"Open Heart."},{"issue":"8","key":"10.1016\/j.cyto.2024.156696_b0160","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ejim.2004.07.013","article-title":"IL-6 levels in acute and post myocardial infarction: their relation to CRP levels, infarction size, left ventricular systolic function, and heart failure","volume":"15","author":"Gabriel","year":"2004","journal-title":"Eur J Intern Med."},{"issue":"9","key":"10.1016\/j.cyto.2024.156696_b0165","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/clc.23017","article-title":"C-reactive protein during and after myocardial infarction in relation to cardiac injury and left ventricular function at follow-up","volume":"41","author":"Vanhaverbeke","year":"2018","journal-title":"Clin. Cardiol."},{"issue":"7","key":"10.1016\/j.cyto.2024.156696_b0170","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/eurheartj\/ehp454","article-title":"Relationship of interleukin-6 with regional and global left-ventricular function in asymptomatic individuals without clinical cardiovascular disease: insights from the Multi-Ethnic Study of Atherosclerosis","volume":"31","author":"Yan","year":"2010","journal-title":"Eur. Heart J."},{"issue":"10","key":"10.1016\/j.cyto.2024.156696_b0175","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","article-title":"Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure","volume":"139","author":"Everett","year":"2019","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.cyto.2024.156696_b0180","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1161\/hc3901.096721","article-title":"Expression of Interleukin-18 in Human Atherosclerotic Plaques and Relation to Plaque Instability","volume":"104","author":"Mallat","year":"2001","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.cyto.2024.156696_b0185","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/clc.23274","article-title":"Interleukin-18 in patients with acute coronary syndromes","volume":"42","author":"\u00c5kerblom","year":"2019","journal-title":"Clin. Cardiol."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466624001996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466624001996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T23:10:27Z","timestamp":1724454627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466624001996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":37,"alternative-id":["S1043466624001996"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2024.156696","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammatory biomarkers and long-term outcome in young patients three months after a first myocardial infarction","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2024.156696","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"156696"}}